

(51) International Patent Classification:
C07K 16/22 (2006.01)(21) International Application Number:
PCT/US2015/000100(22) International Filing Date:
14 September 2015 (14.09.2015)


(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/049,869 12 September 2014 (12.09.2014) US
62/141,775 1 April 2015 (01.04.2015) US(71) Applicant: REGENERON PHARMACEUTICALS,
INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown,
NY 10591 (US).(72) Inventors: HATSELL, Sarah, J.; c/o Regeneron Pharma-
ceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown,
NY 10591 (US). ECONOMIDES, Aris, N.; c/o Regen-
eron Pharmaceuticals, Inc., 777 Old Saw Mill River Road,
Tarrytown, NY 10591 (US). IDONE, Vincent, J.; c/o Re-generon Pharmaceuticals, Inc., 777 Old Saw Mill River
Road, Tarrytown, NY 10591 (US).(74) Agent: CELLI, Rosemarie, L.; Alston & Bird LLP, Bank
of America Plaza, 101 South Tryon Street, Suite 4000,
Charlotte, NC 28280-4000 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,

[Continued on next page]

(54) Title: TREATMENT OF FIBRODYSPLASIA OSSIFICANS PROGRESSIVA



(57) Abstract: Methods for treating Fibrodysplasia Ossificans Progressiva (FOP) are provided. Such methods involve administering to a subject having FOP an effective regime of an activin receptor type 2A (ACVR2A) and/or an activin receptor type 2B (ACVR2B) antagonist or an activin receptor type 1 (ACVR1) antagonist. Antagonists include fusion proteins of one or more extracellular domains (ECDs) of ACVR2A, ACVR2B and/or ACVR1 and the Fc domain of an immunoglobulin heavy chain, and antibodies against ACVR2A, ACVR2B, ACVR1 or Activin A.

Figure 4



DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*